Attributes for Max Diff1 Remission at 36 and 48 weeks2 Accrued duration of remission during 52 weeks3 Time to first relapse4 Reduction of oral glucocorticoid dose during weeks 48 to 525 Composite clinical improvement6 Complete response7 ACQ-6 (Asthma Control Questionnaire) response during weeks 48 to 528 Safety / tolerability9 Dosing and formulation10 Deplete blood eosinophilRemission – defined as a BVAS = 0 and OCS dose ≤4 mg/dayComposite clinical improvement – defined by reaching remission at any time during the study period, or with a ≥50% reduction in oral glucocorticoid dose during weeks 48-52, or no relapses of EGPA during the study period